SCHEMBL6579618

SCHEMBL6579618

CCCCC(=O)c1c(-c2ccc3c(Br)c(OC(Cc4ccccc4)C(=O)O)ccc3c2)oc2ccccc12

nearest known ligand 0.68

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 19/20 0.68
PTPRF P10586 2/20 0.42
PTPRA P18433 2/20 0.42
DUSP3 P51452 2/20 0.42
PTPRC P08575 1/20 0.42
PTPRB P23467 1/20 0.42
PTPN6 P29350 1/20 0.42
PTPN12 Q05209 1/20 0.42
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41
PTPN7 P35236 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6584826 0.93 PTPN1 (0.59) PTPN1PTPRFPTPRADUSP3PTPRC
SCHEMBL6582637 0.92 PTPN1 (0.57) PTPN1PTPRFPTPRADUSP3PPARG
SCHEMBL6581832 0.88 PTPN1 (0.57) PTPN1PTPRFPTPRADUSP3PPARG
SCHEMBL6579699 0.86 PTPN1 (0.61) PTPN1PTPRFPTPRADUSP3PTPRC
SCHEMBL6579715 0.86 PTPN1 (0.50) PTPN1PPARGPPARA
SCHEMBL6581487 0.84 PTPN1 (0.58) PTPN1
SCHEMBL6582638 0.81 PTPN1 (0.49) PTPN1PTPRFPTPRADUSP3PPARG
SCHEMBL6581594 0.81 PTPN1 (0.47) PTPN1
SCHEMBL6580387 0.81 PTPN1 (0.51) PTPN1PPARG
SCHEMBL5413801 0.81 PTPN1 (1.00) PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401822-A1 NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) Wyeth (US) 2004-03-31 EP claimed
US-6599925-B2 Cardiovascular disorders; anticancer agents WYETH 2003-07-29 US claimed
US-20030018067-A1 Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) WYETH 2003-01-23 US claimed
WO-2003000671-A1 NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) WYETH (US) 2003-01-03 WO claimed
EP-1401822-A1 NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) Wyeth (US) 2004-03-31 EP disclosed
US-6599925-B2 Cardiovascular disorders; anticancer agents WYETH 2003-07-29 US disclosed
US-20030018067-A1 Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) WYETH 2003-01-23 US disclosed
WO-2003000671-A1 NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) WYETH (US) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018067-A1 Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) F2R, SERPINE1, SERPINC1 PTPN1 1287/4885PTPRF 1766/4885PTPRA 3313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.